Wolfe Research Begins Coverage on Dianthus Therapeutics (NASDAQ:DNTH)

Key Points

• Wolfe Research initiated coverage of Dianthus Therapeutics (DNTH) with an "outperform" rating and a $98 price target (≈12% upside), while other analysts’ targets range up to $145 and the MarketBeat consensus target is $115.55 with a "Moderate Buy" rating.
• Dianthus reported a Q loss of ($1.43) per share (missing estimates), has a market cap of $3.89 billion and a 1-year trading range of $13.36–$89.72, with sell-side analysts forecasting about -2.61 EPS for the current fiscal year.
• Insiders have sold 314,797 shares worth $25.8 million over the past 90 days (insiders own 8.15% of the stock), while institutional investors hold roughly 47.5% of the company.

Research analysts at Wolfe Research started coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) in a report released on Thursday. The brokerage set an "outperform" rating and a $98.00 price target on the stock. Wolfe Research's target price would suggest a potential upside of 12.03% from the stock's previous close.

Several other research firms have also recently issued reports on DNTH. Raymond James Financial upgraded Dianthus Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their price objective for the stock from $63.00 to $123.00 in a report on Tuesday, March 10th. Oppenheimer raised their price objective on Dianthus Therapeutics to $145.00 and gave the stock an "outperform" rating in a report on Monday, March 9th. Wells Fargo & Company began coverage on Dianthus Therapeutics in a report on Thursday, March 19th. They set an "overweight" rating and a $135.00 price objective on the stock. Jefferies Financial Group set a $98.00 price objective on shares of Dianthus Therapeutics and gave the company a "buy" rating in a research note on Monday, March 9th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a research note on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $115.55.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $87.48 on Thursday. The firm has a 50 day simple moving average of $65.97 and a 200-day simple moving average of $49.05. The firm has a market cap of $3.89 billion, a PE ratio of -21.34 and a beta of 1.22. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $89.72.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.46). The firm had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. As a group, sell-side analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Insider Transactions at Dianthus Therapeutics

In related news, EVP Simrat Randhawa sold 33,830 shares of the stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total transaction of $2,756,468.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marino Garcia sold 122,918 shares of the stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $10,016,587.82. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 314,797 shares of company stock worth $25,825,163 over the last ninety days. 8.15% of the stock is owned by insiders.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd acquired a new stake in Dianthus Therapeutics during the 4th quarter worth approximately $43,000. Seven Fleet Capital Management LP acquired a new position in shares of Dianthus Therapeutics during the 4th quarter valued at $604,000. Invesco Ltd. lifted its holdings in shares of Dianthus Therapeutics by 125.9% during the 4th quarter. Invesco Ltd. now owns 101,489 shares of the company's stock valued at $4,182,000 after acquiring an additional 56,560 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Dianthus Therapeutics during the 4th quarter valued at $550,000. Finally, Voloridge Investment Management LLC lifted its holdings in shares of Dianthus Therapeutics by 80.5% during the 4th quarter. Voloridge Investment Management LLC now owns 39,480 shares of the company's stock valued at $1,627,000 after acquiring an additional 17,612 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.